Literature DB >> 16150117

Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology.

Ian S Scott1, Lesley S Morris, S M Rushbrook, Kate Bird, Sarah L Vowler, Neil G Burnet, Nicholas Coleman.   

Abstract

An immunohistochemical method for assessing cell cycle phase distribution in neurosurgical biopsies would enable such data to be incorporated into diagnostic algorithms for the estimation of prognosis and response to adjuvant chemotherapy in glial neoplasms, without the requirement for flow cytometric analysis. Paraffin-embedded sections of intracerebral gliomas (n = 48), consisting of diffuse astrocytoma (n = 9), anaplastic astrocytoma (n = 8) and glioblastoma (n = 31), were analysed by immunohistochemistry using markers of cell cycle entry, Mcm-2 and Ki67, and putative markers of cell cycle phase, cyclins D1 (G1-phase), cyclin A (S-phase), cyclin B1 (G2-phase) and phosphohistone H3 (Mitosis). Double labelling confocal microscopy confirmed that the phase markers were infrequently coexpressed. Cell cycle estimations by immunohistochemistry were corroborated by flow cytometric analysis. There was a significant increase in Mcm-2 (P < 0.0001), Ki67 (P < 0.0001), cyclin A (P < 0.0001) and cyclin B1 (P = 0.002) expression with increasing grade from diffuse astrocytoma through anaplastic astrocytoma to glioblastoma, suggesting that any of these four markers has potential as a marker of tumour grade. In a subset of glioblastomas (n = 16) for which accurate clinical follow-up data were available, there was a suggestion that the cyclin A:Mcm-2 labelling fraction might predict a relatively favourable response to radical radiotherapy. These provisional findings, however, require confirmation by a larger study. We conclude that it is feasible to obtain detailed cell cycle data by immunohistochemical analysis of tissue biopsies. Such information may facilitate tumour grading and may enable information of prognostic value to be obtained in the routine diagnostic laboratory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150117     DOI: 10.1111/j.1365-2990.2005.00618.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  10 in total

Review 1.  Replication proteins and human disease.

Authors:  Andrew P Jackson; Ronald A Laskey; Nicholas Coleman
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-01-01       Impact factor: 10.005

2.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

3.  Knockdown of MCM10 Gene Impairs Glioblastoma Cell Proliferation, Migration and Invasion and the Implications for the Regulation of Tumorigenesis.

Authors:  Peng Kang; Zhe Han; Zhiyi Liao; Heng Zhang; Wang Jia; Yongji Tian
Journal:  J Mol Neurosci       Date:  2020-02-06       Impact factor: 3.444

4.  MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Authors:  N V Rajeshkumar; Elizabeth De Oliveira; Niki Ottenhof; James Watters; David Brooks; Tim Demuth; Stuart D Shumway; Shinji Mizuarai; Hiroshi Hirai; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

5.  Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study.

Authors:  Mohammed Kassim Chaloob; Hussam Hasson Ali; Ban Jumaa Qasim; Ahmed Salahaldeen Mohammed
Journal:  Oman Med J       Date:  2012-09

6.  Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.

Authors:  Constantinos Giaginis; Maria Georgiadou; Konstantina Dimakopoulou; Gerasimos Tsourouflis; Elisavet Gatzidou; Gregorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

7.  Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.

Authors:  S B Wharton; E Maltby; D A Jellinek; D Levy; N Atkey; S Hibberd; D Crimmins; K Stoeber; G H Williams
Journal:  Acta Neuropathol       Date:  2006-12-09       Impact factor: 17.088

8.  Minichromosome Maintenance (MCM) Family as potential diagnostic and prognostic tumor markers for human gliomas.

Authors:  Cong Hua; Gang Zhao; Yunqian Li; Li Bie
Journal:  BMC Cancer       Date:  2014-07-21       Impact factor: 4.430

9.  Level of phosphohistone H3 among various types of human cancers.

Authors:  Amy Sun; Wei Zhou; Jared Lunceford; Peter Strack; Lisa M Dauffenbach; Christopher A Kerfoot
Journal:  BMJ Open       Date:  2012-10-12       Impact factor: 2.692

10.  Prolactin gene expression in primary central nervous system tumors.

Authors:  Graziella Alebrant Mendes; Júlia Fernanda Semmelmann Pereira-Lima; Maria Beatriz Kohek; Geraldine Trott; Marlise Di Domenico; Nelson Pires Ferreira; Miriam da Costa Oliveira
Journal:  J Negat Results Biomed       Date:  2013-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.